By Application
Hot products 
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Mouse Anti-GST Recombinant Antibody (CBLG1-1938) (CBMAB-G5371-LY)
-
Mouse Anti-BSN Recombinant Antibody (219E1) (CBMAB-1228-CN)
-
Mouse Anti-CD83 Recombinant Antibody (HB15) (CBMAB-C1765-CQ)
-
Mouse Anti-AMOT Recombinant Antibody (CBYC-A564) (CBMAB-A2552-YC)
-
Mouse Anti-His tag Recombinant Antibody (12) (CBMAB-2108CQ)
-
Mouse Anti-GP1BA Recombinant Antibody (6D1) (CBMAB-0271-CN)
-
Mouse Anti-ARIH1 Recombinant Antibody (C-7) (CBMAB-A3563-YC)
-
Mouse Anti-Acetyl-α-Tubulin (Lys40) Recombinant Antibody (V2-623485) (CBMAB-CP2897-LY)
-
Mouse Anti-ENO1 Recombinant Antibody (8G8) (CBMAB-E1329-FY)
-
Mouse Anti-CCS Recombinant Antibody (CBFYC-1093) (CBMAB-C1150-FY)
-
Mouse Anti-A2M Recombinant Antibody (V2-178822) (CBMAB-A0036-YC)
-
Mouse Anti-BrdU Recombinant Antibody (IIB5) (CBMAB-1038CQ)
-
Mouse Anti-AKR1C3 Recombinant Antibody (V2-12560) (CBMAB-1050-CN)
-
Mouse Anti-DDC Recombinant Antibody (8E8) (CBMAB-0992-YC)
-
Mouse Anti-APOE Recombinant Antibody (A1) (CBMAB-0078CQ)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-ELAVL4 Recombinant Antibody (6B9) (CBMAB-1132-YC)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Rabbit Anti-AP2M1 (Phosphorylated T156) Recombinant Antibody (D4F3) (PTM-CBMAB-0610LY)
Ovarian Cancer
Fig.1 Ovarian cancer
Ovarian cancer is a cancer that originates in or on an ovary. Symptoms may include pelvic pain, bloating, abdominal swelling, and loss of appetite. Common areas to which the cancer may spread include the lining of the abdomen, lungs, lymph nodes and liver. The risk of ovarian cancer increases in those women who have ovulated more over their lifetime. This includes those who begin ovulation at a younger age, have never had children or reach menopause at an older age. Other risk factors may include hormone therapy after menopause, obesity and fertility medication. Around 10% of cases are related to inherited genetic risk and women with mutations in the genes of BRCA1 or BRCA2, which have around a 50% chance of developing the disease. The most majority type of ovarian cancer, accounting for more than 95% of cases, is ovarian carcinoma. A blood test for CA-125 is recognized as diagnostic marker for ovarian cancer.
